ANAB – AnaptysBio Inc
AnaptysBio, Inc.ANAB
$20.55Name : AnaptysBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $630,202,688.00
EPSttm : -5.12
AnaptysBio, Inc.
$20.55
7.82%$1.49Float Short %
37.95
Margin Of Safety %
Put/Call OI Ratio
0.91
EPS Next Q Diff
-0.67
EPS Last/This Y
-0.18
EPS This/Next Y
-0.09
Price
20.55
Target Price
37.64
Analyst Recom
1.5
Performance Q
36.73
Relative Volume
0.57
Beta
-0.17
Ticker: ANAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | ANAB | 17.8 | 1.15 | 0.10 | 19881 |
| 2025-03-21 | ANAB | 17.06 | 1.14 | 0.05 | 19893 |
| 2025-03-24 | ANAB | 18.68 | 0.68 | 1.06 | 5541 |
| 2025-03-25 | ANAB | 18.42 | 0.71 | 14.80 | 5869 |
| 2025-03-26 | ANAB | 18.17 | 0.75 | 3.02 | 6026 |
| 2025-03-27 | ANAB | 18.62 | 0.80 | 0.84 | 6254 |
| 2025-03-28 | ANAB | 18.91 | 0.81 | 0.05 | 6664 |
| 2025-03-31 | ANAB | 18.59 | 0.78 | 7.43 | 6774 |
| 2025-04-01 | ANAB | 18.39 | 0.79 | 1.00 | 6817 |
| 2025-04-02 | ANAB | 18.91 | 0.80 | 0.33 | 6819 |
| 2025-04-03 | ANAB | 19.09 | 0.79 | 0.24 | 6865 |
| 2025-04-04 | ANAB | 18.51 | 0.79 | 0.33 | 6847 |
| 2025-04-07 | ANAB | 17.77 | 0.79 | 13.04 | 6842 |
| 2025-04-08 | ANAB | 16.98 | 1.02 | 0.25 | 7887 |
| 2025-04-09 | ANAB | 16.88 | 1.02 | 1.32 | 7905 |
| 2025-04-10 | ANAB | 16.24 | 1.02 | 0.00 | 7907 |
| 2025-04-11 | ANAB | 17.37 | 1.01 | 0.07 | 7922 |
| 2025-04-14 | ANAB | 17.85 | 0.97 | 1.46 | 8077 |
| 2025-04-15 | ANAB | 18.08 | 0.98 | 0.23 | 8157 |
| 2025-04-16 | ANAB | 19.06 | 0.92 | 0.06 | 8582 |
| 2025-04-17 | ANAB | 20.52 | 0.91 | 0.05 | 8635 |
| 2025-04-18 | ANAB | 20.55 | 0.91 | 0.09 | 8635 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | ANAB | 17.57 | 10.8 | -81.4 | -5.62 |
| 2025-03-21 | ANAB | 17.03 | 10.8 | -31.0 | -5.62 |
| 2025-03-24 | ANAB | 18.71 | 10.8 | -91.4 | -5.62 |
| 2025-03-25 | ANAB | 18.44 | 10.8 | -39.2 | -5.62 |
| 2025-03-26 | ANAB | 18.19 | 10.8 | -39.5 | -5.62 |
| 2025-03-27 | ANAB | 18.64 | 10.8 | -54.9 | -5.62 |
| 2025-03-28 | ANAB | 18.95 | 10.8 | -51.1 | -5.62 |
| 2025-03-31 | ANAB | 18.59 | 10.8 | -37.9 | -5.62 |
| 2025-04-01 | ANAB | 18.40 | 10.8 | -3.8 | -5.30 |
| 2025-04-02 | ANAB | 18.97 | 10.8 | -16.0 | -5.30 |
| 2025-04-03 | ANAB | 19.25 | 10.8 | -10.8 | -5.30 |
| 2025-04-04 | ANAB | 18.52 | 10.8 | 4.1 | -5.30 |
| 2025-04-07 | ANAB | 17.75 | 10.8 | 5.3 | -5.30 |
| 2025-04-08 | ANAB | 16.98 | 10.8 | 7.3 | -5.30 |
| 2025-04-09 | ANAB | 16.87 | 10.8 | -4.3 | -5.30 |
| 2025-04-10 | ANAB | 16.24 | 10.8 | 7.0 | -5.30 |
| 2025-04-11 | ANAB | 17.13 | 10.8 | -28.7 | -5.30 |
| 2025-04-14 | ANAB | 17.86 | 10.8 | -20.4 | -5.30 |
| 2025-04-15 | ANAB | 18.10 | 10.8 | -10.8 | -5.30 |
| 2025-04-16 | ANAB | 19.06 | 10.8 | -23.2 | -5.30 |
| 2025-04-17 | ANAB | 20.55 | 10.8 | -28.4 | -5.30 |
| 2025-04-18 | ANAB | 20.55 | 10.8 | -6.9 | -5.30 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | ANAB | 3.20 | 15.25 | 31.91 |
| 2025-03-21 | ANAB | 3.20 | 15.25 | 31.91 |
| 2025-03-24 | ANAB | 3.20 | 15.25 | 31.91 |
| 2025-03-25 | ANAB | 3.27 | 15.25 | 31.91 |
| 2025-03-26 | ANAB | 3.27 | 15.25 | 34.63 |
| 2025-03-27 | ANAB | 3.27 | 15.25 | 34.63 |
| 2025-03-28 | ANAB | 3.27 | 15.25 | 34.63 |
| 2025-03-31 | ANAB | 3.27 | 15.17 | 34.64 |
| 2025-04-01 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-02 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-03 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-04 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-07 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-08 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-09 | ANAB | 3.26 | 15.17 | 34.64 |
| 2025-04-10 | ANAB | 3.26 | 15.17 | 37.95 |
| 2025-04-11 | ANAB | 3.26 | 15.17 | 37.95 |
| 2025-04-14 | ANAB | 3.26 | 15.16 | 37.95 |
| 2025-04-15 | ANAB | 3.26 | 15.16 | 37.95 |
| 2025-04-16 | ANAB | 3.26 | 15.16 | 37.95 |
| 2025-04-17 | ANAB | 3.26 | 15.16 | 37.95 |
| 2025-04-18 | ANAB | 3.26 | 15.16 | 37.95 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.72
Avg. EPS Est. Current Quarter
-1.46
Avg. EPS Est. Next Quarter
-1.39
Insider Transactions
3.26
Institutional Transactions
15.16
Beta
-0.17
Average Sales Estimate Current Quarter
13
Average Sales Estimate Next Quarter
9
Fair Value
Quality Score
27
Growth Score
51
Sentiment Score
86
Actual DrawDown %
50.3
Max Drawdown 5-Year %
-69.3
Target Price
37.64
P/E
Forward P/E
PEG
P/S
6.9
P/B
8.84
P/Free Cash Flow
EPS
-5.2
Average EPS Est. Cur. Y
-5.3
EPS Next Y. (Est.)
-5.39
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-159.1
Relative Volume
0.57
Return on Equity vs Sector %
-224.9
Return on Equity vs Industry %
-211.5
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.64
EBIT Estimation
-6.9
AnaptysBio, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 136
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading